Microbiota Transfer Improves Gastrointestinal and Autism Symptoms: An OPEN Label Study
Objectives: Determine the safety and possible efficacy of MTT for treating GI and ASD symptoms.
Methods: An open-label clinical trial of MTT involved a two-week antibiotic treatment, a bowel cleanse, and then an extended duration of fecal microbiota transplant (FMT) using a high initial dose followed by daily lower maintenance doses for 7-8 weeks.
Results: The Gastrointestinal Symptom Rating Scale (GSRS) revealed an approximately 80% reduction of GI symptoms at the end of treatment, including significant improvements in symptoms of constipation, diarrhea, indigestion, and abdominal pain, and all those benefits remained improved at 8 weeks after treatment. Similarly, clinical assessments showed that behavioral ASD symptoms improved significantly, and remained improved at 8 weeks after treatment ended.
Conclusions: This exploratory, extended-duration treatment protocol thus appears to be a promising approach to improve GI and behavioral symptoms of ASD. Improvements in GI symptoms and ASD symptoms persisted for at least 8 weeks after treatment ended, suggesting a long-term impact.